Benzinga

DECEMBER 13, 2023

Integra LifeSciences Holdings Corporation (NASDAQ: IART ) agreed to acquire Acclarent Inc. from Ethicon Inc , a Johnson & Johnson (NYSE: JNJ ) MedTech company, for $275 million in cash, and an additional $5 million upon the achievement of certain regulatory milestones. Acclarent offers medical devices for ENT procedures.

59

59

Benzinga

APRIL 1, 2024

April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc. , PRINCETON, N.J., a pioneer in ear, nose and throat (ENT) surgical interventions.

Technology 45

Technology Marketability 45

Benzinga

MAY 16, 2023

Maravai LifeSciences Holdings Inc (NASDAQ: MRVI ) reportedly attracted takeover interest from Thomas H. Lee Partners with a non-binding offer, though the offer price could not be learned. Maravai is a U.S. provider of capping reagents for COVID-19 vaccines.

Equity 52

Equity 52

Benzinga

DECEMBER 6, 2022

06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA). About Integra LifeSciences Integra LifeSciences is a global leader. PRINCETON, N.J.,

Technology 40

Technology 40

Benzinga

DECEMBER 13, 2023

13, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ), a global leader in medical technology, today announced that it has entered into a definitive agreement to acquire Acclarent , Inc. PRINCETON, N.J., from Ethicon, Inc., We are looking forward to welcoming the Acclarent employees to the Integra team.

Technology 40

Technology Marketability 40

Benzinga

DECEMBER 20, 2023

20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. IRVINE, Calif.,

Banking 40

Banking 40

Benzinga

DECEMBER 1, 2022

executive vice president and president, Tissue Technologies, Integra LifeSciences. "By Acquisition will add distinct new product solution for plastic and reconstructive surgery to address clinical needs and improve patient outcomes. Deploys capital to support strong profitable growth and greater returns for our shareholders. PRINCETON, N.J.,

Technology 40

Technology Marketability 40